INTRODUCTION {#S5}
============

The escalating rate of obesity worldwide ([@R5]; [@R20]; [@R36]) is associated with an increasing prevalence of type 2 diabetes (T2DM) ([@R32]). One mechanism by which obesity may contribute to the pathogenesis of T2DM is that the increased flux of FFAs from lipolysis in visceral adipose tissue causes insulin resistance and impairs pancreatic β-cell function ([@R21]; [@R12]; [@R18]).

Epidemiological studies have shown that a high intake of dietary fibre, especially insoluble fibre from whole grains (nonviscous, slowly fermentable fibre), is associated with a lower risk for type 2 diabetes ([@R8]; [@R26]; [@R25]; [@R16]) and increased insulin sensitivity ([@R15]). The mechanisms by which insoluble fibres reduce diabetes risk are largely unknown, but, maybe via colonic fermentation. Improved insulin sensitivity has been observed after short-term consumption of purified insoluble fibres which appear to be independent of the rate of colonic fermentation ([@R31]). Other factors may therefore also be involved, an accelerated GIP response after insoluble fibre enrichment was described as a potential mechanism linking cereal fibre intake to the reduced risk of diabetes ([@R31]). Colonic fermentation of dietary fibre may exert an insulin-sensitizing effect through the production of the short chain fatty acids (SCFAs), acetate, propionate and butyrate. SCFA may modulate insulin sensitivity by reducing fatty acid flux. Oral ingestion ([@R6]) and rectal infusion of acetate ([@R34]) leads to reduced serum free-fatty acid (FFA) concentrations and feeding fermentable carbohydrate also reduces serum FFA concentrations ([@R13]; [@R9]; [@R4]; [@R28]).

It is known that both production and absorption rates of colonic SCFA differ between individuals, and that glucose tolerance status affects serum SCFA concentrations in humans who are insulin resistant but nondiabetic ([@R33]). This suggests that insulin resistance may alter SCFA metabolism. Studies have not been done that specifically look at markers of colonic fermentation (ie. breath hydrogen and methane and SCFA concentrations) and FFA concentrations in insulin resistant subjects. Serum SCFA concentrations in normal and hyperinsulinemic humans after ingestion of fibre has not been compared before. Therefore, the main objective of this preliminary study was to determine if differences exist in breath hydrogen and methane and the SCFA response after acute ingestion of the non-digestible oligosaccharide inulin in healthy humans without T2DM who are insulin resistant compared with those who are insulin sensitive.

METHODS {#S6}
=======

Male or non-pregnant, non-lactating females aged 18--65 with BMI ≥ 20 and ≤ 35kg/m^2^ were recruited from a pool of subjects previously involved in similar studies. Subjects were excluded for any of the following reasons: history of diabetes, cardiovascular disease or bowel, kidney or liver disease; use of medications which affect blood glucose or insulin sensitivity (such as diuretics); use of antibiotics within 3 months of starting the study; or following any unusual dietary practices. Eligible subjects were then screened with a fasting blood sample; subjects were excluded for any of the following reasons: serum glucose ≥ 7.0 mmol/L, triglycerides ≥ 4.0 mmol/L, hematocrit (HCT) \< 0.345 (the lower limit of normal) or aspartate transaminase \> 1.5 times the upper limit of normal. Eligible subjects were divided prospectively to obtain a group (n = 9) with normal fasting insulin (FSI \< 40pmol/L) and a group (n = 9) with high fasting insulin (FSI ≥ 40pmol/L). Subjects were selected based on FSI because of the positive association between FSI and insulin resistance ([@R37]), and because 40 pmol/L represents approximately the 66^th^ percentile for healthy subjects, based on previous studies in our lab. Ethical approval for the study was obtained from the Research Ethics Boards of St. Michael's Hospital, Toronto and the University of Toronto. Subjects gave written informed consent to participate in the study.

All tests were conducted at the Clinical Nutrition and Risk Factor Modification Centre (CNRFMC) of St. Michael's Hospital, Toronto. Subjects were studied on two mornings, separated by 13 ± 2 days, after 10 -- 14-h overnight fasts. Tests were administered in a random order. Subjects were asked to refrain from alcohol consumption and any abnormally strenuous exercise in the 24 h period prior to all test days.

On the day of the test, subjects collected fasting breath samples. An indwelling catheter was inserted into a superficial forearm vein and kept patent with normal saline and fasting blood samples were collected. The subjects then consumed a test drink containing 75 g glucose (Glucose) (Grain Process Enterprises Ltd, Scarborough, ON) or 75 g glucose + 24 g Oliggo-Fiber® Instant Inulin (Cargill Inc, Wayzata, MN) (Inulin) dissolved in 300 mL of water. They consumed the test drink over 5 min, and were given an additional 200 mL of water to drink over 15 min. Blood samples were collected at 30, 60, 90, 120, 180, and 240 min following consumption of the test drink for the measurement of glucose, insulin, C-peptide, free fatty acids and SCFA. Breath samples, for analysis of breath hydrogen and methane concentrations, were collected every half hour for 4 h following consumption of the test drink.

Whole blood for glucose, insulin, C-peptide, FFA and SCFA measurements were collected in red top Vacutainer^™^ tubes (Becton Dickinson, Franklin Lakes, NJ). Serum glucose was measured by a glucose oxidase method (SYNCHRON LX Systems, Beckman Coulter, Brea, CA) (inter-assay CV 1.9%), insulin using the Beckman Access Ultrasensitive Insulin method (Beckman Instruments, Fullerton, CA) (inter-assay CV 2.5 to 4.3%) and c-peptide by a highly specific double-antibody RIA (Siemens Medical Solutions Diagnostics, Los Angeles, CA) (inter- assay CV ≤10%). Blood samples for serum FFA and SCFA were allowed to clot at room temperature, centrifuged at 600 × g for 15 min at 4 °C, and the serum aliquoted and stored at −70 °C before analysis. FFA were measured by an enzymatic technique that used acylCoA oxidase(Wako Diagnostics, Wako Chemicals, USA, Inc) (inter-assay CV of \<1.5%).

SCFA were measured by gas chromatography after micro filtration and vacuum distillation. An 1.2--1.5 mL aliquot of serum was filtered through a micropartition system with a 30 kDa MWCO Vivaspin RC (VS02H22) filters (Sartorius Inc., Mississauga, ON) by centrifugation at 5000 × *g* at 4 °C for 90 min. The protein-free filtrate was stored at −20 °C before vacuum distillation ([@R30]). Distillation was performed by using a 225 μL sample of protein-free serum to which was added a 25 μL internal standard solution consisting of 1.25 mM valeric acid and 1.06 M formic acid. An automatic sampler (HP 7673; Hewlett- Packard, Mississauga, ON) was used to inject 1 μL aliquots of sample into a gas chromatograph (HP 5890 Series II; Hewlett-Packard) equipped with a direct-cool, on-column inlet, an Agilent HP-FFAP column (30m × 0.53mm × 1.0 μm film), Agilent 19095F-123 (Agilent Technologies Canada Inc., Mississauga, ON), and a flame ionization detector.

Subjects collected breath samples using the Easy Sampler ^™^ with tube holder (Quintron Instrument Company, Milwaukee, WI). Methane and hydrogen were measured by gas chromatography (Quintron Microlyzer, Model SC, Milwaukee, WI) in breath samples and simultaneously obtained room air. Breath hydrogen and methane concentrations reported were adjusted by subtracting the hydrogen and methane of room air from that of each breath sample collected.

Statistical analysis was performed with SPSS version 17 for WINDOWS (SPSS Inc., Chicago, IL) using the General Linear Model (GLM) repeated-measures analysis of variance (ANOVA) examining for the main effects of group, treatment and time, and interactions between these three effects. Since there were only two treatments and two groups, post hoc tests were not performed in SPSS. Post hoc analysis using Bonferroni post-tests was done using GraphPad Prism 5 for Windows, Version 5.02 (GraphPad Software Inc., La Jolla, CA) when main effects were identified by ANOVA. Differences with P-values ≤ 0.05 were considered to be statistically significant.

Since a significant time × treatment × group interaction was not observed for any variable, data for study variables are presented in two ways. [Figures 1](#F1){ref-type="fig"} & [2](#F2){ref-type="fig"} compare postprandial responses between NI and HI subjects; the values at each time point represent the mean response for Glucose and Inulin. [Figures 3](#F3){ref-type="fig"} & [4](#F4){ref-type="fig"} compare postprandial responses between Glucose and Inulin; the values at each time point represent the mean for all subjects. A main effect of group was observed for acetate, insulin and c-peptide.

Incremental areas under the curve (AUC), ignoring the area beneath the baseline, were also calculated geometrically for the 0--4h period, using a Microsoft Office Excel 2003 (Microsoft Corp) spreadsheet. Statistical analysis was done on the AUC using analysis of variance (ANOVA) examining for the main effects of group and treatment and interactions between these two effects. Differences with P-values ≤ 0.05 (2-tailed) were considered to be statistically significant. The results are expressed as means ± SEM.

RESULTS {#S7}
=======

We studied 11 women and 7 men with a mean (± SEM) age of 36.4 ± 9.0 y and BMI 26.9 ± 3.7 kg/m^2^. Subjects with HI had significantly higher waist circumference, serum insulin, triglycerides and total cholesterol/HDL ratio and a significantly lower HDL concentration than NI subjects ([Table 1](#T1){ref-type="table"}). Inulin was well tolerated and participants reported no adverse reactions after consumption. The mean fasting concentrations for serum SCFA, breath gases, plasma glucose, insulin, C-peptide, and FFA did not differ between the two test days.

All measured variables except methane varied significantly with time. Responses in NI differed from those in HI with a significant main effect of group for insulin, c-peptide ([Figure 1](#F1){ref-type="fig"}) and acetate ([Figure 2](#F2){ref-type="fig"}) and a significant time×group interaction for glucose, insulin, and FFA ([Figure 1](#F1){ref-type="fig"} & [2](#F2){ref-type="fig"}). Incremental AUC for insulin and c-peptide were significantly greater in HI compared to NI subjects ([Table 2](#T2){ref-type="table"}). Serum insulin was significantly higher in HI than NI at 60 (p \< 0.05; Bonferroni correction), 90 and 120 min (p \< 0.001; Bonferroni correction), and c-peptide higher in HI than NI at 90 and 120 min (p \<0.01; Bonferroni correction; [Figure 1](#F1){ref-type="fig"}). The rise in serum glucose from 0--30 min was similar in HI and NI, but its fall was delayed by 30--60 min in HI compared to NI. Similarly the fall and subsequent rebound of FFA was delayed by about 30 min in HI compared to NI. However, despite the significant time×group interaction none of the differences in glucose or FFA between HI and NI was significant at any individual time point ([Figure 1](#F1){ref-type="fig"} & [2](#F2){ref-type="fig"}).

Fasting (p \<0.01; Bonferroni correction) and postprandial serum acetate was significantly higher in NI compared to HI subjects ([Figure 2](#F2){ref-type="fig"}). Overall the mean serum-acetate concentration over the 4 h study period was higher in NI than HI subjects (43.7 ± 6.6 vs 22.5 ± 3.7 μmol/L, p = 0.02) and the acetate AUC was significantly greater in NI compared to HI subjects (p \< 0.05, [Table 2](#T2){ref-type="table"}).

A significant time × treatment × group interaction was not observed for any variable which indicates that Inulin had a similar effect on all measured variables in NI and HI subjects. There were no significant differences in glucose, insulin, C-peptide, FFA and SCFA AUC between the Glucose and Inulin treatments in both groups ([Table 2](#T2){ref-type="table"}). In all subjects combined, Inulin had no significant effect on plasma glucose, insulin and c-peptide responses compared to Glucose ([Figure 3](#F3){ref-type="fig"}). There was a significant main effect of treatment and a significant time × treatment interaction for FFA ([Figure 4](#F4){ref-type="fig"}). Serum FFA rebounded significantly more slowly after Inulin than Glucose (0.0021 ± 0.0002 vs 0.0033 ± 0.0004 mEq/L/min, p = 0.006), and serum-FFA was significantly lower 4 h after Inulin than Glucose (0.310 ± 0.028 vs 0.432 ± 0.042 mEq/L, p \< 0.01; Bonferroni correction). There was also a significant time × treatment interaction (p=0.001) for serum acetate with acetate falling initially after both test meals, but then tending to rise more quickly and to a greater extent after Inulin compared to Glucose, however the difference in serum acetate between Inulin and Glucose was not significant at any point in time ([Figure 4](#F4){ref-type="fig"}); in addition there was no significant difference in acetate AUC. Serum propionate and butyrate concentrations tended to be higher 240 min after Inulin than Glucose, but the differences were not significant.

Breath hydrogen and methane responses did not differ significantly between NI and HI subjects. The breath hydrogen and methane responses were significantly higher after Inulin than Glucose in both groups (significant time × treatment interaction, p \< 0.001 and p = 0.002, respectively. Breath hydrogen and methane AUC were also significantly greater after Inulin than Glucose in both groups ([Table 2](#T2){ref-type="table"}).

DISCUSSION {#S8}
==========

The significance of colonic fermentation of dietary fibre and the role of SCFA in enhancing insulin sensitivity and reducing the risk of T2DM has been the subject of studies in normal ([@R23], [@R22]) and hyperinsulinemic humans ([@R10]). But, studies so far have not compared colonic fermentation of dietary fibre in normal and hyperinsulinemic humans. The main objective of this preliminary study was to compare markers of colonic fermentation ie. breath hydrogen and methane and serum SCFA responses in subjects with normal plasma insulin (NI) and those with high plasma insulin (HI) concentrations after 75 g glucose (Glucose) and 75 g glucose plus 24 g inulin (Inulin). The results showed that inulin had similar effects on breath hydrogen and methane and serum SCFA concentrations in NI compared to HI subjects, but that fasting and postprandial serum acetate concentrations were significantly higher in NI compared to HI subjects.

Although breath hydrogen and methane and serum SCFA are short-term markers of colonic fermentation, the breath gases are known to increase 1--2 hours after inulin ingestion, whereas serum SCFA take longer to respond. Our results are consistent with this in that we observed significant increases in breath hydrogen and methane after inulin, whereas tendency toward increases in serum SCFA responses was no statistically significant. The latter indicates that a longer study period may be required to observe changes in SCFA concentrations. In an earlier study in normals over a 6 h period, 24 g inulin plus 56 g high fructose corn syrup significantly increased postprandial acetate, propionate and butyrate responses ([@R28]), with acetate concentrations peaking at 4.5 h over the 6 h study period, propionate at 5 h and butyrate at \~5.5 h ([@R28]). The longer study period, and the fact that subjects consumed a standard lunch at 4 h may explain the discrepancy with our results. The SCFA response after Inulin did not differ between the two groups suggesting that exogenous production of SCFA may be similar in NI and HI subjects. Inulin is a prebiotic as it selectively stimulates growth and/or activity of bifidobacteria ([@R11]). A possible criticism of this study is that inulin is mainly fermented by bifidobacteria and may not involve other gut microbial species in its colonic fermentation. However, a study in batch cultures which confirmed the bifidogenic effect of inulin also indicated that other intestinal microbial groups grew on its carbon sources ([@R24]). It was observed that bifidobacteria grew by cross-feeding on the mono- and oligosaccharides produced by primary inulin intestinal degraders. Therefore, the colonic fermentation of inulin may be a complex process involving many metabolic pathways, carried out by numerous species which are interdependent on each other.

Interestingly, lower serum acetate concentrations were seen in HI compared to NI subjects. Previous work has not linked hyperinsulinemia to low acetate concentrations. Fasting serum acetate is increased in T2DM ([@R1], [@R29]; [@R34]), but increased concentrations of fasting serum acetate were not observed in obese or impaired glucose tolerant subjects ([@R33]). Theoretically, a lower acetate concentration in HI subjects may be explained by decreased production (endogenous or exogenous) or decreased absorption or increased clearance. Our results showed that serum acetate after Inulin was similar in NI and HI subjects, this suggests that the lower acetate concentration in HI subjects may result from a decreased endogenous production of acetate. The significantly lower fasting acetate concentration in HI subjects also points to reduced endogenous production as, after an overnight fast, serum acetate is mainly derived from endogenous sources. In NI subjects, the acetate nadir was reached significantly more quickly at 77 ± 13 min compared to 133 ± 16 min in HI subjects (p = 0.02). This sharp fall in acetate in NI subjects may be explained by the suppressive effect of insulin on fat oxidation and, therefore, endogenous acetate release and the rebound may be due to the loss of this suppressive effect of insulin. But, in HI subjects a similar scenario was not observed as hyperinsulinemia may alter endogenous acetate production. Additionally, the delayed fall in serum acetate in HI subjects was paralleled by a delayed fall in FFA which suggests that endogenous acetate production associated with fat oxidation is normal in the NI group but it may be altered in the HI group.

Endogenous acetate metabolism is facilitated by two enzymes, acetyl-CoA synthetase (ACAS) and acetyl-CoA hydrolase. Mammals possess two isoforms of ACAS, one cytosolic and the other mitochondrial. The activity of the cytosolic enzyme (ACAS1), found predominantly in the liver, activates acetate to supply cells with acetyl-CoA for lipid synthesis ([@R17]). ACAS1 activity responds to changes in nutritional and hormonal status and in vitro studies have shown that it is regulated by insulin ([@R7]; [@R14]; [@R27]). Fasting reduces transcription levels for ACAS1, while refeeding restores them. The ACAS gene was downregulated in streptozotocin-induced diabetic mice and was restored after insulin replacement, suggesting that diabetic status and insulin also regulate this gene ([@R27]). Studies measuring acetate and glucose turnover in insulin resistant obese and diabetic subjects have also shown that acetate metabolism is sensitive to insulin action (Piloquet *et al*., 2002). It is unclear if the insulin resistance in the HI subjects in our study contributed to the altered acetate metabolism in this group possibly through the actions of insulin on ACAS1 gene expression.

Lowering postprandial FFA improves insulin sensitivity and insulin secretion ([@R2]; [@R3]). The hypothesis that SCFA modulate insulin sensitivity through alterations in fatty acid flux ([@R35]) has been tested in several studies ([@R23], [@R22]), but their results are equivocal. It has been suggested that acetate reduces serum FFA by suppressing adipose tissue lipolysis ([@R1]). In addition, there is evidence that acetate produced as a byproduct of microbial fermentation of dietary fibre in the human colon reduces plasma FFA concentrations and improves insulin sensitivity ([@R13]; [@R9]; [@R4]; [@R28]). Thus high concentrations of colonic acetate may have beneficial effects in the peripheral circulation on adipose tissue lipolysis and may lead to a decrease in insulin resistance by lowering FFA concentrations. Conversely, low concentrations of SCFA or the inability of SCFA to regulate FFA may contribute to the development of obesity and insulin resistance.

In an earlier study ([@R28]), feeding healthy subjects 24 g of inulin significantly increased SCFA responses and this was associated with a reduced postprandial FFA concentration. In the present study a significant main effect of treatment and a significant time × treatment interaction was observed for FFA, but, FFA AUC did not significantly differ after Inulin between NI and HI subjects. In the earlier study ([@R28]), FFA response was measured over a 6h period, therefore, a longer study period may be required to observe changes in FFA response after inulin.

In conclusion, this study shows that acute inulin ingestion increases short-term markers for colonic fermentation in NI and HI subjects as evidenced by increases in breath hydrogen and methane. But a longer study period may be necessary to observe significant increases in the serum SCFA response. The lower serum acetate concentration in HI subjects may be related to an altered endogenous acetate metabolism in this group. But, more studies are needed to see if differences in SCFA absorption and clearance between the two groups are also involved.
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![Mean (± SEM) plasma glucose, insulin and c-peptide concentrations after Glucose and Inulin in NI and HI subjects. A significant main effect of group was observed for insulin (p = 0.003) and c-peptide (p \< 0.01). A significant group × time interaction was observed for glucose (p = 0.01) and insulin (p \< 0.001). Within a time point, labelled means without a common letter differ (a vs b, p \<0.01; c vs d, p \< 0.05; e vs f, p \< 0.001; Bonferroni post-test after demonstration of significant main effect of group by ANOVA).](nihms4024f1){#F1}

![Mean (± SEM) FFA, serum acetate, propionate and butyrate concentrations after Glucose and Inulin in NI and HI subjects. A significant main effect of group was observed for acetate (p = 0.01). A significant group × time interaction was observed for FFA (p = 0.001). Within a time point, labelled means without a common letter differ (a vs b, p \<0.01; Bonferroni post-test after demonstration of significant main effect of group by ANOVA).](nihms4024f2){#F2}

![Mean (± SEM) plasma glucose, insulin and c-peptide concentrations after Glucose and Inulin in all 18 subjects. No significant main effect of treatment was observed for any variable.](nihms4024f3){#F3}

![Mean (± SEM) FFA, serum acetate, propionate and butyrate concentrations after Glucose and Inulin in all 18 subjects. A significant main effect of treatment was observed for FFA (p = 0.03) along with a significant time × treatment interaction (p \< 0.001). A significant time × treatment interaction was also observed acetate (p = 0.02). Within a time point, labelled means without a common letter differ (a vs b, p \<0.01; Bonferroni post-test after demonstration of significant main effect of treatment by ANOVA).](nihms4024f4){#F4}

###### 

Characteristics of the normal and hyperinsulinaemic subjects at the screening visit[1](#TFN1){ref-type="table-fn"}

                                     Normal        Hyperinsulinemics   P-value
  ---------------------------------- ------------- ------------------- ---------
  Age (y)                            35.9 ± 3.8    36.9 ± 2.2          0.8
  M:F                                4 : 5         3 : 6               
  BMI (kg/m^2^)                      25.4 ± 1.5    28.4 ± 0.7          0.1
  Waist Circumference (cm)           87.7 ± 2.7    95.1 ± 1.4          0.03
  Systolic blood pressure (mm Hg)    109 ± 3       118 ± 3             0.06
  Diastolic blood pressure (mm Hg)   68 ± 3        77 ± 4              0.08
  Glucose (mmol/L)                   5.0 ± 0.1     5.1 ± 0.2           0.65
  Insulin (pmol/L)                   29.4 ± 2.0    76.7 ± 12.0         0.004
  HCT (L/L)                          0.39 ± 0.01   0.39 ± 0.01         0.91
  AST (U/L)                          18.9 ± 1.3    21.9 ± 1.6          0.16
  CRP (mg/L)                         2.5 ± 1.8     2.7 ± 0.7           0.91
  Cholesterol (mmol/L)               4.7 ± 0.2     5.3 ± 0.4           0.23
  Triglycerides (mmol/L)             0.91 ± 0.12   1.78 ± 0.3          0.02
  HDL (mmol/L)                       1.42 ± 0.06   1.08 ± 0.08         0.004
  TC/HDL                             3.33 ± 0.18   4.93 ± 0.31         0.001
  LDL (mmol/L)                       2.84 ± 0.21   3.39 ± 0.30         0.16

Values are means ±SEM.

###### 

Incremental areas under the curve for glucose, insulin, C-peptide, FFA and short chain fatty acids (SCFAs) after glucose and inulin in normal (NI) and hyperinsulinemic (HI) subjects.

  -----------------------------------------------------------------------------------------------------
                                  Treatment   Group           P-value                           
  ------------------------------- ----------- --------------- -------------- ---------- ------- -------
  Glucose (mmol × min·L^−1^)      Glucose\    279 ± 103\      361 ± 78\      0.095      0.813   0.481
                                  Inulin      201 ± 50        400 ± 88                          

  Insulin (nmol × min·L^−1^)      Glucose\    35.1 ± 7.0\     94.3 ± 19.0\   \< 0.001   0.949   0.817
                                  Inulin      32.8 ± 6.0      98.5 ± 17.7                       

  C-peptide (nmol × min·L ^−1^)   Glucose\    233 ± 51\       358 ± 47\      \< 0.01    0.745   0.707
                                  Inulin      230 ± 51        393 ± 48                          

  FFA (mEq × min·L^−1^)           Glucose\    −48.8 ± 8.4\    −42.0 ± 7.7\   0.811      .0916   0.875
                                  Inulin      −40.5 ± 10.2    −41.3 ± 10.5                      

  Acetate (μmol × min·L^−1^)      Glucose\    −5577 ± 1989\   −2054 ± 692\   0.027      0.393   0.979
                                  Inulin      −4238 ± 2090    −796 ± 436                        

  Propionate (μmol × min·L^−1^)   Glucose\    −124 ± 58\      0 ± 21\        0.091      0.390   0.149
                                  Inulin      −34 ± 43        −24 ± 18                          

  Butyrate (μmol × min·L^−1^)     Glucose\    −24 ± 18\       0 ± 6\         0.986      0.098   0.142
                                  Inulin      27 ± 25         4 ± 7                             

  Hydrogen (ppm × min)            Glucose\    −595 ± 405\     −546 ± 224\    0.735      0.023   0.785
                                  Inulin      983 ± 1314      1442 ± 523                        

  Methane (ppm × min)             Glucose\    −88 ± 154\      −538 ± 409\    0.486      0.025   0.773
                                  Inulin      846 ± 666       659 ± 426                         
  -----------------------------------------------------------------------------------------------------

**Note:** Values are means ± SEM for *n* = 18 subjects.
